Last reviewed · How we verify
Intravenous (IV) abatacept
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | Intravenous (IV) abatacept |
|---|---|
| Also known as | BMS-188667, Orencia |
| Sponsor | Bristol-Myers Squibb |
| Drug class | CTLA-4 fusion protein; T-cell costimulation inhibitor |
| Target | CD80, CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Abatacept works by interrupting the second signal required for full T-cell activation. It consists of the extracellular domain of CTLA-4 fused to the Fc portion of IgG1, allowing it to bind CD80 and CD86 molecules on antigen-presenting cells. This prevents the interaction between these molecules and CD28 on T cells, effectively dampening the adaptive immune response and reducing inflammatory cytokine production.
Approved indications
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus
Common side effects
- Infection (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Hypertension
- Serious infections
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant (PHASE2)
- Rheumatoid Arthritis Memory B Cells and Abatacept (PHASE4)
- Belatacept Early Steroid Withdrawal Trial (PHASE4)
- Sjogrens Syndrome Measured by Ultrasound (PHASE2)
- Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) (PHASE2)
- Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous (IV) abatacept CI brief — competitive landscape report
- Intravenous (IV) abatacept updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI